Jun-Chao Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun-Chao Jin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Feng Li
The Affiliated Tumor Hospital of Harbin Medical University, 6 BaoJian Road, NanGang District, Harbin, 150086, The People's Republic of China
2 shared publications - Chun-Peng Zhang
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, PR China
2 shared publications - Hongsheng Chen
Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, 150001 Harbin, Heilongjiang, China
2 shared publications - Jia-Ren Liu
Department of Clinical Laboratory The Forth Affiliated Hospital of Harbin Medical University Harbin China
2 shared publications - Jinlu Zhao
Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
2 shared publications - Lei Wang
Treatment Center of Oncology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, PR China
2 shared publications
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 7 (1) , 84
Fresh raspberry phytochemical extract inhibits hepatic lesion in a Wistar rat model
Red raspberry possesses potent antioxidant capacity and antiproliferative activity against cancer in vitro.
- 1 January 2010
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 7 (1) , 84
Open AccessFresh raspberry phytochemical extract inhibits hepatic lesion in a Wistar rat model
Red raspberry possesses potent antioxidant capacity and antiproliferative activity against cancer in vitro.
- Open Access
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 16
Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls
Colorectal cancer (CRC) is often diagnosed at a late stage with concomitant poor prognosis. The hypersensitive analytical technique of proteomics can detect molecular changes before the tumor is palpable. The surface-enhanced laser desorption/ionization-time of flight-mass spectra (SELDI-TOF-MS) is a newly-developed technique of evaluating protein separation in recent years. The protein chips have established the expression of tumor protein in the serum specimens and become the newly discovered markers for tumor diagnosis. The objective of this study was to find new markers of the diagnosis among groups of CRC, colorectal benign diseases (CBD) and healthy controls. The assay of SELDI-TOF-MS with analytical technique of protein-chip bioinformatics was used to detect the expression of protein mass peaks in the sera of patients or controls. One hundred serum samples, including 52 cases of colorectal cancer, 27 cases of colorectal benign disease, and 21 cases of healthy controls, were examined by SELDI-TOF-MS with WCX2 protein-chips.
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 16
Open AccessDifferential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls
Colorectal cancer (CRC) is often diagnosed at a late stage with concomitant poor prognosis. The hypersensitive analytical technique of proteomics can detect molecular changes before the tumor is palpable. The surface-enhanced laser desorption/ionization-time of flight-mass spectra (SELDI-TOF-MS) is a newly-developed technique of evaluating protein separation in recent years. The protein chips have established the expression of tumor protein in the serum specimens and become the newly discovered markers for tumor diagnosis. The objective of this study was to find new markers of the diagnosis among groups of CRC, colorectal benign diseases (CBD) and healthy controls. The assay of SELDI-TOF-MS with analytical technique of protein-chip bioinformatics was used to detect the expression of protein mass peaks in the sera of patients or controls. One hundred serum samples, including 52 cases of colorectal cancer, 27 cases of colorectal benign disease, and 21 cases of healthy controls, were examined by SELDI-TOF-MS with WCX2 protein-chips.